Matthias Schroff, Exicure CEO
In survival mode, Exicure cuts to the bone — pausing all R&D and chopping headcount by 66%
The drastic restructuring that Exicure undertook at the end of last year couldn’t save the biotech after all.
In fact, Exicure — whose take on gene …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
